IHS Chemical Week

Regions :: Western Europe :: Germany

Wacker, XL-protein sign cooperation agreement to produce biopharmaceuticals

7:38 AM MST | November 5, 2012 | Deepti Ramesh

Wacker says that its Wacker Biotech (Jena, Germany) subsidiary and XL-protein (Freising, Germany), a privately owned biopharmaceutical company, have signed an agreement to collaborate more intensely on the production of PASylated therapeutic proteins. Through this collaboration, Wacker and its customers will gain access to XL-protein’s PASylation platform. The PASylation technology enables the development of biopharmaceuticals with extended plasma half-lives, which require less frequent injection and thus are more patient friendly, Wacker says. In a recent...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2012 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa